Detalhe da pesquisa
1.
Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort.
Alzheimers Dement
; 19 Suppl 9: S42-S48, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37296082
2.
Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection.
Alzheimers Dement
; 19 Suppl 9: S8-S18, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37256497
3.
Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease.
Alzheimers Dement
; 19 Suppl 9: S49-S63, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37496307
4.
White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS).
Alzheimers Dement
; 19 Suppl 9: S89-S97, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37491599
5.
Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study.
Alzheimers Dement
; 19 Suppl 9: S115-S125, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37491668
6.
Pathogenic variants in the Longitudinal Early-onset Alzheimer's Disease Study cohort.
Alzheimers Dement
; 19 Suppl 9: S64-S73, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37801072